Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Target Price at $37.50

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $37.50.

A number of equities analysts have recently issued reports on INKT shares. HC Wainwright upgraded shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Friday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. B. Riley raised shares of MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Finally, Wall Street Zen lowered MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd.

MiNK Therapeutics Trading Down 3.1%

Shares of INKT stock opened at $13.23 on Thursday. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company has a market capitalization of $59.80 million, a P/E ratio of -4.59 and a beta of 0.33. The stock has a 50 day moving average of $14.40 and a two-hundred day moving average of $12.64.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). Sell-side analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.